More than £6M of funding has been awarded to enhance the development of biopharmaceuticals.
In total £6.5M will fund 12 projects to deliver commercially important results, such as industrial-scale production of antibodies, stem cell preservation at room temperature, biopharmaceutical production using microbes and commercial scale stem cell therapy.
The funding is the second round of awards from Phase 2 of the Bioprocessing Research Industry Club (BRIC), a partnership between the Biotechnology and Biological Sciences Research Council (BBSRC), the Engineering and Physical Sciences Research Council (EPSRC), a consortium of leading companies and HealthTech and Medicines Knowledge Transfer Network.
Bioprocessing is the use of living cells or their components (e.g. enzymes) to manufacture desirable products. The innovative projects will investigate new tools and methods for bioprocessing which will be of particular benefit to the biopharmaceutical sector, where developing new drugs is often slow, expensive and complicated.
The UK biopharmaceutical sector comprises over 250 companies and it is forecast that, by 2016, eight of the top ten 'blockbuster' medicines will be biologics rather than conventional small molecules. The sector is of huge importance to the UK economy.
The new research will take place at nine UK universities. BRIC-funded research addresses bioprocesses at all scales of operation, from the small amounts required for pre-clinical studies through to post-licence mass manufacture.
Priority areas for BRIC research include bioprocessing for protein products and their host cell producers, high-throughput bioprocess development, effective modelling of whole bioprocesses, robust and effective analytics for bioprocessing and bioprocessing research for cellular products.
Dr Celia Caulcott, BBSRC Director, Innovation and Skills, said: "This latest investment in bioprocessing research through BRIC will further enhance our ability to manufacture the biopharmaceuticals of the future in an efficient and sustainable way. It is a timely prelude to our continuing support for bioprocessing research under our Industrial Biotechnology and Bioenergy Strategy."
Mr Atti Emecz, EPSRC Director Strategy and Business Relationships, said: "This investment demonstrates the value of the BRIC approach. It draws together bioscience, chemistry and engineering to tackle multidisciplinary challenges and promote internationally excellent research. It also develops the valuable partnerships with industry needed to deliver impact."
Ten BRIC Studentships have also been funded by BBSRC to help develop the bioprocessing researchers of the future. This brings the total number of BRIC students to 28, each with a collaborating BRIC member company.
BRIC Studentships are collaborative training grants, which follow the Industrial CASE model, giving these top bioprocessing PhD students the chance to experience first-rate research at both an academic institution and within an industrial setting.
The ten studentships will start in the 2013/14 academic year, and last for up to four years, based at five UK universities in partnership with six collaborating companies/organisations.
Students will spend a minimum of three months in a placement with the industrial partner learning skills that they will not necessarily acquire during a standard doctoral programme.
As well as providing high-quality training the scheme develops networking links between students, academia and industry.
The programme complements the EPSRC-funded Doctoral Training Centres at Newcastle and UCL that are relevant to the bioprocessing sector and other EPSRC studentship investments, by supporting training with a biosciences focus.
The funded BRIC research projects are:
Notes to editors:
The UK biopharmaceutical sector comprises over 250 companies and it is forecast that, by 2016, eight of the top ten 'blockbuster' medicines will be biologics rather than conventional small molecules: Evaluate Pharma Market Report 2010.
The Biotechnology and Biological Sciences Research Council (BBSRC) invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond. Funded by Government, and with an annual budget of around £500M (2012-2013), we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
For more information about BBSRC, our science and our impact see: http://www.bbsrc.ac.uk
The Engineering and Physical Sciences Research Council (EPSRC) is the main UK government agency for funding research and training in engineering and the physical sciences. Working with UK universities, it invests around £800m a year in world class research and training that has real impact on future economic development and improved quality of life.
tel: 01793 414694
fax: 01793 41338
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.